Stock comparison
BioMarin Pharmaceutical
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BMRN
BioMarin Pharmaceutical
Market cap
$10.45B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BMRN | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 58D | 77B | LMAT |
| Benjamin Graham | 57D | 89A | LMAT |
| Philip Fisher | 55C | 81C | LMAT |
| Peter Lynch | 47D | 67B | LMAT |
| Joel Greenblatt | 28F | 56D | LMAT |
| Charlie Munger | 45D | 68D | LMAT |
| Terry Smith | 52D | 69D | LMAT |
Side-by-side metrics
| Metric | BMRN | LMAT |
|---|---|---|
| Market cap | $10.45B | $2.23B |
| P/E (TTM) | 38.7x | 37.1x |
| EV/EBIT | 18.1x | 36.6x |
| ROIC (TTM) | 3.92% | 9.43% |
| Gross margin | 75.93% | 72.39% |
| Net margin | 8.29% | 24.35% |
| Revenue CAGR 5y | 14.93% | 12.75% |
| EPS CAGR 5y | 2.29% | 19.04% |
| Debt / Equity | 0.2x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BMRN leads on
- EPS CAGR 5y2.29%vs 19.04%+92%
- Market cap$10.45Bvs $2.23B+79%
- EV/EBIT18.1xvs 36.6x+50%
- Debt / Equity0.2xvs 0.5x+50%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 8.29%+66%
- ROIC (TTM)9.43%vs 3.92%+58%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.